Ankyra Therapeutics is a clinical-stage biotech developing anchored-drug conjugates to trigger long lasting anti-tumor response without compromising safety.

Ankyra Therapeutics

Ankyra Therapeutics | 1,812 followers on LinkedIn. Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response | Ankyra is developing a novel approach for cancer treatment called Anchored Immunotherapy, promoting prolonged immune activation locally while limiting systemic toxicity.

Co-founder/Managing Partner, Borealis Ventures

Phil Ferneau

Experienced Quality Assurance professional

Dayna Resi

Lynn Nicole (Dickerson)

Chief Process and Manufacturing Officer at Ankyra Therapeutics

Greg Zarbis-Papastoitsis

Ankyra Therapeutics announces the first visceral tumor patient dosed #anchoredimmunotherapy #anchoreddrugconjugates https://shorturl.at/nclWG

Ankyra Therapeutics is excited to announce the appointment of Julia G. Butchko, Ph.D. and Tara Withington, CAE to the Ankyra Board of Directors. https://shorturl.at/UHkXq

Ankyra Therapeutics President and CEO Howard Kaufman will be speaking at today's SITC Summit on Intralesional Immunotherapy #SITC #Anchoredimmunotherapy #immunotherapy

Come see Ankyra Therapeutics Trial in Progress poster, A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors, at 9am CDT located at 158A #ASCO https://lnkd.in/ecSv2fxn

Ankyra Therapeutics President and CEO will be the featured speaker at Drug Discovery News upcoming webinar about Combination therapy for Cancer on April 18, 2024 at 1pm ET https://lnkd.in/exKhS5NZ

Ankyra Therapeutics has announced an exclusive licensing agreement for JEN-001 with Jenga Biosciences. https://lnkd.in/eXsQxYd2

Ankyra Therapeutics is excited to announce the first patient has been dosed in our Phase 1 clinical trial evaluating ANK-101, an Anchored Immune Medicine, for the treatment of solid tumors. Read more in the press release: https://rb.gy/n6vaw7

The Ankyra Therapeutics team proudly participated in the Life Science Cares Boston #Holidayhelpers program this holiday season.

This month, results from a preclinical study demonstrating potent anti-tumor activity of our lead program ANK-101 were published in the December issue of The Journal of Clinical Investigation Insight. Data from the study on ANK-101, a novel tumor-directed anchored immune medicine (AIM), demonstrated retention at the tumor site for approximately four weeks, overcoming the challenges of intratumoral injection. To read more and to view the paper, "Intratumoral aluminum hydroxide-anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment": https://lnkd.in/euwp_NEF

ANKY

COM:ANKYRATX

Ankyra Therapeutics